Skip to main content

Advertisement

ADVERTISEMENT

Podcasts

Headshot of John Tesser, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
03/02/2023
Maria Asimopoulos
John RP Tesser, MD, rheumatology specialist, Arizona Arthritis & Rheumatology Associates, and clinical adjunct professor, Midwestern University College of Health Sciences, discusses the MIRROR trial, a study which showed the addition of an...
John RP Tesser, MD, rheumatology specialist, Arizona Arthritis & Rheumatology Associates, and clinical adjunct professor, Midwestern University College of Health Sciences, discusses the MIRROR trial, a study which showed the addition of an...
John RP Tesser, MD, rheumatology...
03/02/2023
First Report Managed Care

Advertisement

Craig Gravina, chief technology officer, ObvioHealth
Podcasts
02/27/2023
Edan Stanley
Craig Gravina, chief technology officer, ObvioHealth, sheds some light on the current digital therapeutics landscape, including regulatory challenges, the prescription DTx model, and solutions to improve clinical trial research.
Craig Gravina, chief technology officer, ObvioHealth, sheds some light on the current digital therapeutics landscape, including regulatory challenges, the prescription DTx model, and solutions to improve clinical trial research.
Craig Gravina, chief technology...
02/27/2023
First Report Managed Care
Gary Owens, MD, headshot on blue background
Podcasts
02/15/2023
Gary Owens, MD, discusses how payers might develop formularies for prescription digital therapeutics, as well as what metrics may be used to determine their efficacy.
Gary Owens, MD, discusses how payers might develop formularies for prescription digital therapeutics, as well as what metrics may be used to determine their efficacy.
Gary Owens, MD, discusses how...
02/15/2023
First Report Managed Care
Headshot of Gary Owens on a blue background underneath the PopHealth Perspectives logo.
Podcasts
02/01/2023
Maria Asimopoulos
Gary Owens, MD, president, Gary Owens Associates, discusses the ALPINE study and predicts how zanubrutinib's recently approved indication for chronic lymphocytic leukemia will transform the standard of care.
Gary Owens, MD, president, Gary Owens Associates, discusses the ALPINE study and predicts how zanubrutinib's recently approved indication for chronic lymphocytic leukemia will transform the standard of care.
Gary Owens, MD, president, Gary...
02/01/2023
First Report Managed Care

Advertisement

Headshot of Chuck Thigpen, ATI Physical Therapy, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
12/22/2022
Maria Asimopoulos
Chuck Thigpen, PhD, PT, ATC, clinical research scientist, ATI Physical Therapy, reviews the updated guidance on pain management from the Centers for Disease Control and Prevention, as well as how patients and payers typically cover the costs...
Chuck Thigpen, PhD, PT, ATC, clinical research scientist, ATI Physical Therapy, reviews the updated guidance on pain management from the Centers for Disease Control and Prevention, as well as how patients and payers typically cover the costs...
Chuck Thigpen, PhD, PT, ATC,...
12/22/2022
First Report Managed Care
Headshots of Edmund Pezalla, Adam Kittai, Farrukh Awan, Jeffrey Dunn
Podcasts
12/21/2022
Maria Asimopoulos
Adam Kittai, MD, hematology specialist and assistant professor of medicine, Ohio State University; Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center; and Jeffrey Dunn, PharmD, MBA, chief clinical officer,...
Adam Kittai, MD, hematology specialist and assistant professor of medicine, Ohio State University; Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center; and Jeffrey Dunn, PharmD, MBA, chief clinical officer,...
Adam Kittai, MD, hematology...
12/21/2022
First Report Managed Care
Headshot of Farrukh Awan, MD, UT Southwestern Medical Center
Podcasts
12/21/2022
Maria Asimopoulos
Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center, offers insight into how a new second-generation BTK inhibitor might impact the treatment paradigm in chronic lymphocytic leukemia.
Farrukh Awan, MD, professor of internal medicine, UT Southwestern Medical Center, offers insight into how a new second-generation BTK inhibitor might impact the treatment paradigm in chronic lymphocytic leukemia.
Farrukh Awan, MD, professor of...
12/21/2022
First Report Managed Care

Advertisement

Headshot of Jeffrey Dunn, PharmD, MBA, Cooperative Benefits Group
Podcasts
12/21/2022
Maria Asimopoulos
Jeffrey Dunn, PharmD, MBA, chief clinical officer, Cooperative Benefits Group, discusses the rationale driving coverage for new and existing drugs and shares how US stakeholders account for metrics like quality of life.
Jeffrey Dunn, PharmD, MBA, chief clinical officer, Cooperative Benefits Group, discusses the rationale driving coverage for new and existing drugs and shares how US stakeholders account for metrics like quality of life.
Jeffrey Dunn, PharmD, MBA, chief...
12/21/2022
First Report Managed Care
Headshot of Alan Vernon, CQ Fluency, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
12/20/2022
Maria Asimopoulos
Alan Vernon, vice president of health care solutions, CQ Fluency, reviews how many people in the United States do not speak English as their primary language and offers advice for payers and providers to keep patients engaged in their care.
Alan Vernon, vice president of health care solutions, CQ Fluency, reviews how many people in the United States do not speak English as their primary language and offers advice for payers and providers to keep patients engaged in their care.
Alan Vernon, vice president of...
12/20/2022
Integrated Healthcare Executive
Headshot of Omar Sinno, UCB, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
12/08/2022
Maria Asimopoulos
Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.
Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.
Omar Sinno, MD, MBA, medical...
12/08/2022
First Report Managed Care

Advertisement

Advertisement